Unknown

Dataset Information

⁸⁹Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer.


ABSTRACT:

Purpose

Given the bone tropism of prostate cancer, conventional imaging modalities poorly identify or quantify metastatic disease. (89)Zr-huJ591 positron emission tomography (PET) imaging was performed in patients with metastatic prostate cancer to analyze and validate this as an imaging biomarker for metastatic disease. The purpose of this initial study was to assess safety, biodistribution, normal organ dosimetry, and optimal imaging time post-injection for lesion detection.

Methods

Ten patients with metastatic prostate cancer received 5 mCi of (89)Zr-huJ591. Four whole-body scans with multiple whole-body count rate measurements and serum activity concentration measurements were obtained in all patients. Biodistribution, clearance, and lesion uptake by (89)Zr-huJ591 immuno

SUBMITTER: Pandit-Taskar N 

PROVIDER: S-EPMC4404641 | biostudies-literature | 2014 Nov

REPOSITORIES: biostudies-literature